Philips receives FDA 510(k) clearance for next-generation reusable SpO₂ clip sensor

Rhea-AI Summary

Philips (NYSE: PHG) received FDA 510(k) clearance for its next-generation reusable SpO₂ clip sensor, designed to improve pulse oximetry reliability across diverse patient populations and clinical conditions. The sensor uses internal optical refinements to enhance signal quality and measurement consistency.

In desaturation studies, the sensor achieved an Accuracy Root Mean Square (ARMS) of 1.6%, compared with the 3% level recommended by ISO and recognized by the FDA. Accuracy varied by less than 0.5% between light and dark skin pigmentation groups in an SaO₂ range of 85–100%. The device is supported by Philips’ validation program aligned with FDA guidance and ISO/IEC standards and will be introduced in select global markets later this year. Philips reported 2025 sales of EUR 18 billion and operates in more than 100 countries.

Positive

• FDA 510(k) clearance for next-generation reusable SpO₂ clip sensor
• Sensor ARMS accuracy of 1.6% vs 3% ISO/FDA recommendation
• Skin-tone accuracy variation of <0.5% between light and dark groups
• Philips 2025 sales of EUR 18 billion provide scale for commercialization

Negative

• New SpO₂ clip sensor initially available only in select markets
• Published performance data based on internal validation studies, not external outcomes
• No quantified revenue or earnings impact disclosed for the new sensor

News Market Reaction – PHG

-0.64%

-0.64% Session close to close

In the Jul 21 session, PHG declined 0.64%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

PHG's June 17 patient-monitor launch was followed by a -2.09% 24-hour move, underscoring varied hist...

Analysis

PHG's June 17 patient-monitor launch was followed by a -2.09% 24-hour move, underscoring varied historical reactions to product news. The clearance's validation evidence is the key event-specific anchor; low short positioning remains a sourced risk context.

Key Figures

FDA clearance: 510(k) ARMS: 1.6% ISO/FDA recommended level: 3% +5 more

8 metrics

FDA clearance 510(k) Next-generation reusable Philips SpO₂ clip sensor

ARMS 1.6% Desaturation studies

ISO/FDA recommended level 3% Pulse oximetry performance reference

Accuracy variation Less than 0.5% Between light and dark skin pigmentation groups

SaO₂ evaluation range 85-100% Validation testing across skin pigmentation groups

2025 sales EUR 18 billion Royal Philips 2025 sales

Employees Approximately 64,800 employees Royal Philips company profile

Global reach More than 100 countries Sales and services footprint

Historical Context

5 past events · Latest: Jul 08 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 08	AI ultrasound launch	Positive	-2.3%	Alturion ultrasound system received FDA 510(k) clearance and CE mark
Jul 07	AI toothbrush launch	Positive	+0.3%	Sonicare introduced electric toothbrush with on-device AI guidance
Jun 29	Monitoring contract	Positive	+0.4%	University Health selected Philips enterprise monitoring platform under EMaaS
Jun 17	Patient monitor launch	Positive	-2.1%	Philips introduced IntelliVue Patient Monitor 6000 Series for healthcare providers
Jun 09	AI impact report	Positive	+2.7%	Future Health Index reported clinician time savings and workflow benefits from AI

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent positive Philips announcements produced mixed 24-hour reactions, ranging from -2.3% to +2.69%.

Key Terms

510(k), accuracy root mean square, ARMS, pulse oximetry, +1 more

5 terms

510(k) regulatory

"announced FDA 510(k) clearance of its next-generation reusable Philips"

A 510(k) is a U.S. regulatory submission that a medical device maker uses to show a new device is as safe and effective as an already-approved device, allowing the regulator to clear it for sale rather than requiring the longer, more stringent approval process. For investors, a cleared 510(k) usually means lower regulatory risk and a faster path to market, which can speed revenue generation and reduce uncertainty—similar to proving a new appliance works like a trusted existing model.

accuracy root mean square medical

"achieved an Accuracy Root Mean Square (ARMS) value of 1.6%"

A statistical measure that summarizes how close a set of predicted or measured values are to the actual values by squaring each error, averaging those squares, and taking the square root. It produces a single number in the same units as the data that reflects the typical size of prediction or measurement errors; think of it as the average distance of darts from the bullseye. For investors, it signals the reliability of forecasts, models, or reported figures used in valuation and risk analysis.

ARMS medical

"Accuracy Root Mean Square (ARMS) value of 1.6%"

Adjustable-rate mortgages (ARMs) are home loans with interest rates that can change over time, usually after an initial fixed-rate period. Like a streetlight that can switch brightness, the monthly payment can rise or fall as benchmark interest rates move, which affects homeowners’ cash flow and the value and risk of mortgage-backed assets that investors may hold or trade.

pulse oximetry medical

"Pulse oximetry is one of the most widely used monitoring technologies"

Pulse oximetry is a noninvasive way to estimate how much oxygen is in a person’s blood using a small sensor—commonly clipped to a finger, toe, or earlobe—that also reads pulse rate. For investors, it matters because this measurement is a common feature in medical and consumer health devices; its accuracy, regulatory status, and demand influence product adoption, sales, and the perceived reliability of companies that make or use the technology.

SpO₂ medical

"reusable Philips SpO₂ clip sensor"

SpO₂ is the percentage of oxygen carried in the blood as measured noninvasively by a pulse oximeter placed on a finger or earlobe, like a quick reading of how full a tank is. Investors track SpO₂ because it is a simple clinical indicator of respiratory and overall health that drives demand for medical devices, home-monitoring products, treatments, and hospital services, and it can influence regulatory outcomes and reimbursement decisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

July 21, 2026

New sensor advances pulse oximetry reliability for diverse patient populations through innovation and rigorous validation.


Cambridge, MASS – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced FDA 510(k) clearance of its next-generation reusable Philips SpO₂ clip sensor, reinforcing the company's ongoing commitment to providing clinicians with trusted oxygen saturation measurements that support confident care for every patient.


The enhanced sensor incorporates internal optical refinements to further improve signal quality and measurement consistency, supporting reliable SpO₂ measurements across diverse patient populations and clinical conditions.


In desaturation studies, the reusable clip sensor achieved an Accuracy Root Mean Square (ARMS) value of 1.6%, which is nearly twice as accurate as the 3% level recommended by ISO and recognized by the FDA [1]. The sensor also demonstrated consistent performance across a broad range of skin tones, with accuracy varying by less than 0.5% between the light and dark skin pigmentation groups evaluated within an SaO₂ range of 85-100% [1]. These results reflect Philips' rigorous approach to sensor development and validation, with the company's SpO₂ sensor portfolio consistently meeting applicable regulatory performance expectations.


"Providing clinicians with reliable data to deliver better care to more people is at the heart of everything we do," said Sachin Chaudhari, Category Leader, Clinical Measurements and Specialty Monitoring at Philips. "This FDA clearance reflects our ongoing investment in advancing sensor technology and rigorous validation practices, and we'll continue applying these innovations across our pulse oximetry portfolio so clinicians can make care decisions with even greater confidence.”

Pulse oximetry is one of the most widely used monitoring technologies in healthcare, providing clinicians with critical information to assess a patient's oxygenation status. Because signal quality can be influenced by a range of physiological, clinical and technical factors, Philips takes a comprehensive approach to developing and evaluating its sensor technologies, combining continuous innovation with rigorous testing designed to support reliable performance in real-world, diverse care environments.


The FDA-cleared reusable clip sensor is backed by Philips' comprehensive pulse oximetry validation program, which evaluates performance across diverse patient populations—including varying skin tones—and a broad range of physiological and clinical conditions. Philips' validation practices align with evolving FDA recommendations and applicable international standards, including those established by the International Organization for Standardization (ISO) and the International Electrotechnical Commission (IEC).

Philips continues to collaborate with clinicians, researchers, regulators and standards organizations to strengthen the science behind pulse oximetry and support the continued evolution of validation practices. Through ongoing investment in research, innovation and clinical evidence, Philips is helping advance pulse oximetry that clinicians can trust to perform consistently across diverse skin tones and patient physiological conditions.

The FDA-cleared reusable Philips SpO₂ clip sensor will become available in select markets across the globe later this year.

Click here to learn more about Philips pulse oximetry portfolio.
 
[1] Philips internal data on file. Performance results are based on validation testing conducted.

For further information, please contact:

Allison Johnson
Business Communication Director, Philips
Tel: +16176317305


Jayme Maniatis
Philips Global External Relations
Tel: +16178948368

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.


Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2025 sales of EUR 18 billion and employs approximately 64,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment

• Philips SpO₂ Clip Sensor

FAQ

What did Philips (PHG) announce on July 21, 2026 about its SpO₂ clip sensor?

Philips announced FDA 510(k) clearance for its next-generation reusable SpO₂ clip sensor. According to Philips, the sensor introduces internal optical refinements to improve signal quality and measurement consistency across diverse patients and clinical conditions, supporting more reliable oxygen saturation monitoring in real-world care environments.

How accurate is the new Philips (PHG) reusable SpO₂ clip sensor?

The new Philips SpO₂ clip sensor achieved an Accuracy Root Mean Square (ARMS) of 1.6%. According to Philips, this compares with the 3% ARMS level recommended by ISO and recognized by the FDA, indicating substantially tighter measurement error in desaturation validation studies conducted by the company.

How does the Philips (PHG) SpO₂ clip sensor address skin tone accuracy concerns?

The sensor showed less than 0.5% accuracy variation between light and dark skin pigmentation groups. According to Philips, testing covered an SaO₂ range of 85–100% and is part of a broader validation program designed to support consistent pulse oximetry performance across diverse patient populations and conditions.

When will the FDA-cleared Philips (PHG) reusable SpO₂ clip sensor be available?

The reusable Philips SpO₂ clip sensor will be introduced in select global markets later this year. According to Philips, the cleared device will expand its pulse oximetry portfolio, with rollout timing and market selection managed within the company’s broader monitoring and clinical measurements strategy.

What does FDA 510(k) clearance of the Philips (PHG) SpO₂ sensor mean for investors?

FDA 510(k) clearance allows Philips to market its next-generation reusable SpO₂ clip sensor in the U.S. According to Philips, the product enhances its monitoring portfolio, but the company has not disclosed specific revenue, margin, or earnings contributions linked to this sensor at this stage.

How does the new Philips (PHG) SpO₂ clip sensor relate to regulatory standards?

The sensor’s 1.6% ARMS performance is compared to the 3% ARMS level recommended by ISO and recognized by the FDA. According to Philips, its validation practices align with evolving FDA recommendations and international ISO and IEC standards for pulse oximetry devices and testing.